Molecular biomarkers are characteristics of a tumor that can, in some cases, be used to help make decisions about therapies. Biomarker testing is now available to lung cancer patients including tests for epidermal growth factor receptor (EGFR) mutation analysis.
Researcher from the San Diego Cancer Center clinical oncology gives us a comprehensive overview of biomarkers in lung cancer today, and of the new and exciting targeted treatments both on the market now and in clinical trials. We discusses the importance of getting a biopsy on a tumor so that you'll have enough tissue for molecular testing now and in the future as new biomarkers are discovered.
Links from show notes
https://www.biodesix.com/lung-diagnostics/continuum-care/treatment-blr/veristrat
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30475-7/fulltext
https://stemcellthailand.org/oncology/lung-cancer-treatment/
https://www.futuremedicine.com/doi/10.2217/lmt-2019-0009